Pharmacology
From leech biology to three FDA-approved pharmaceuticals
Medicinal leech biology has directly inspired three FDA-approved direct thrombin inhibitors and contributed to the conceptual development of oral anticoagulants used by millions of patients worldwide (bivalirudin alone is used in over 1 million PCI procedures annually; Stone et al., N Engl J Med, 2008; PMID: 18832246). The leech accounts for half of all zoopharmaceutical FDA approvals.
Important Distinction
The Translational Pipeline
Topics
Direct Thrombin Inhibitors
The DTI drug class: from native hirudin to bivalirudin and dabigatran — a four-decade journey.
Explore →
Bivalirudin
Class I recommendation for STEMI PCI. HORIZONS-AMI: 43% reduction in cardiac mortality. ~$596M peak revenue.
Explore →
Oral Anticoagulants
Dabigatran and the DOAC revolution — conceptual lineage from leech hirudin crystallography.
Explore →
Leech Extracts
Piyavit and whole-extract formulations: international pharmacology, not FDA-cleared.
Explore →
Drug Pipeline
Destabilase, decorsin, saratin, eglin C — next-generation candidates from the leech secretome.
Explore →
Laboratory Effects
APTT, INR, platelet monitoring, and laboratory parameter changes during hirudotherapy.
Explore →
By the Numbers
3
FDA-Approved DTIs
$596M
Peak Bivalirudin Revenue
200+
Bioactive Proteins
99%+
Unexploited as Drug Leads